key: cord-0961487-jcqxx7f0 authors: López-Medrano, Francisco; Pérez-Jacoiste Asín, María Asunción; Fernández-Ruiz, Mario; Carretero, Octavio; Lalueza, Antonio; Maestro de la Calle, Guillermo; Caro, José Manuel; de la Calle, Cristina; Catalán, Mercedes; García-García, Rocío; Martínez-López, Joaquín; Origüen, Julia; Ripoll, Mar; San Juan, Rafael; Trujillo, Hernando; Sevillano, Ángel; Gutiérrez, Eduardo; de Miguel, Borja; Aguilar, Fernando; Gómez, Carlos; Silva, José Tiago; García-Ruiz de Morales, Daniel; Saro-Buendía, Miguel; Marrero-Sánchez, Ángel; Chiara-Graciani, Guillermo; Bueno, Héctor; Paz-Artal, Estela; Lumbreras, Carlos; Pablos, José L.; Aguado, José María title: Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study date: 2021-02-26 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.099 sha: 98833a768d30911eb6e98fbc3a76c38d1e56bfce doc_id: 961487 cord_uid: jcqxx7f0 Background The role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear. Methods We conducted a retrospective single-center study including consecutive patients ≥65 years that developed severe COVID-19 between March 3 and May 1, 2020 and were treated with corticosteroids at various doses (methylprednisolone [0.5 mg/Kg/12 hours to 250 mg/24 hours]), either alone (“CS group”) or associated to intravenous tocilizumab (400-600 mg, one to three doses) (“CS-TCZ group”). Primary outcome was all-cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and/or a ≥2-point decrease on a six-point ordinal scale) by day +14. Propensity score (PS)-based adjustment and inverse probability of treatment weights (IPTW) were applied. Results Overall, 181 and 80 patients were included in the CS and CS-TCZ groups. All-cause 14-day mortality was lower in the CS-TCZ group, both in the PS-adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17 – 0.68; P-value = 0.002) and IPTW-weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21 – 0.68; P-value = 0.001). This protective effect was also observed for 28-day mortality (PS-adjusted HR: 0.38; 95% CI: 0.21 – 0.72; P-value = 0.003). Clinical improvement by day +14 was higher in the CS-TCZ group in the IPTW analysis only (OR: 2.26; 95% CI: 1.49 – 3.41; P-value <0.001). The occurrence of secondary infection was similar between both groups. Conclusions The combination of corticosteroids and TCZ was associated with better outcomes among patients ≥65 years with severe COVID-19. to-moderate course, although a significant proportion of patients will ultimately develop acute respiratory distress syndrome (ARDS) , which carries a high mortality rate . Older age has been consistently identified as a risk factor for death and poor outcomes in COVID- 19 . For example, a report of 72,314 cases from China found case-fatality rates of 8% and 15% for patients aged 70-79 years and >80 years, respectively, in contrast with an overall rate as low as 2.3% for the global cohort . In the United Kingdom the risk of death for COVID-19 patients older than 80 years was 20-fold higher than those between 50 and 59 (Williamson et al., 2020) . J o u r n a l P r e -p r o o f This retrospective cohort study was conducted at the University Hospital "12 de Octubre" a 1,300-bed tertiary care center located in the urban area of Madrid (Spain). The Clinical Research Ethics Committee approved the study protocol and granted a waiver of informed consent due to its observational design. Given the relatively low baseline prescription rate and the marked surge in demand early after J o u r n a l P r e -p r o o f the beginning of the pandemic, there was a shortage of TCZ during the first weeks of March. The interdisciplinary committee decided to distribute, on a daily basis, the available doses according to three principles: a) the fulfillment of the previously detailed inclusion and exclusion criteria; b) the absence of a short-term life-threatening condition; c) and, providing that both previous criteria were met, the drug was preferably administered to those patients with a longer life expectancy. As a result, during the month of March TCZ was more commonly prescribed to younger patients, whereas corticosteroids alone were widely used for patients ≥65 years. As the incidence of SARS-CoV-2 infection declined and the supply of TCZ increased, an increasing proportion of patients ≥65 years received this immunomodulatory drug from April, 2020. This circumstance allowed us to compare two cuasi-contemporary cohorts of aged patients treated with different immunomodulatory regimens: corticosteroids alone during the first period (March, 2020 ["CS group"]), and corticosteroids associated to TCZ during the second period (April and May, 2020 ["CS-TCZ group"]). The primary outcome was all-cause mortality by day +14 after the first dose of the immunomodulatory therapy. Secondary outcomes included all-cause mortality by day +28 and clinical improvement by day +14 (defined as discharge to home and/or a decrease of ≥2 points from day 0 on the six-point ordinal scale). Quantitative data were shown as the mean and standard deviation (SD) or the median with interquartile range (IQR), whereas qualitative variables were expressed as absolute and relative 1b) . A landmark analysis on those patients surviving ≥4 days (n = 208) confirmed the benefit survival by day +28 among patients in the CS-TCZ group (Figure 2 In view of the presence of baseline imbalances between both groups, we constructed the PS for receiving TCZ associated to corticosteroids (CS-TCZ group) on the basis of those clinical and analytical variables present at day 0. The following measured predictors were included: age, Caucasian ethnicity, obesity, chronic lung disease, chronic heart disease, dementia, Charlson comorbidity index, cough at presentation, time since symptom onset, SpO2/FiO2 ratio <316 at whereas clinical cure by day +7 was higher in the IPTW-adjusted model only ( Table 3) . These associations remained essentially unchanged in the landmark analysis restricted to hospitalized patients surviving at +4 ( Table S1 in Supporting Material). The diagnosis of superinfection beyond day 0 was made in 6.1% (11/181) and 3.8% Therefore, we applied PS adjustment and IPTW to take into account these differences operating J o u r n a l P r e -p r o o f in opposite senses, and still found significant risk reductions in the primary study outcome ranging from 57% to 66% (according to the adjusted model) in favor of the combination of corticosteroids and TCZ. On the other hand, and despite the lack of apparent impact in the crude comparison, the odds for achieving clinical response by day +14 was also significantly higher in the CS-TCZ group after balancing potential confounders by IPTW. Nevertheless, this association should be taken with caution since it was not confirmed in PS-adjusted models. Although it was to be expected that the old age of our patients (77.2 ± 7.7 years) would have put them at an increased risk of TCZ-associated adverse events, no significant differences were found in the occurrence of bacterial or fungal infectious complications between study groups. There are a number of limitations in our study to be acknowledged. First, due to its retrospective J o u r n a l P r e -p r o o f observational design, the impact of unmeasured confounders cannot be completely ruled out, even after PS-based and IPTW adjustments. As discussed above, the direction of potential bias is not obvious in view of the nature of baseline imbalances, since patients in the CS group were older and had a higher burden of comorbidities (including chronic lung disease and dementia), whereas those in the CS-TCZ group showed increased disease severity by day 0 (as suggested by lower SpO2/FiO2 ratio and lymphocyte counts and higher LDH levels). As previously pointed, more patients were admitted to the ICU in the CS-TCZ group than in the CS group, likely reflecting their lower age. However, we found no significant differences in mortality rates between patients admitted to the ICU and those staying in the hospitalization ward. Likewise, J o u r n a l P r e -p r o o f a The propensity score for receiving TCZ therapy in association to corticosteroids (versus corticosteroids alone) included the following variables: age, Caucasian ethnicity, obesity, chronic lung disease, chronic heart disease, dementia, Charlson comorbidity index, cough at presentation, time since symptom onset, SpO2/FiO2 ratio <316 at day 0, lymphocyte count at day 0, LDH level at day 0, and bilateral alveolar infiltrates at day 0. b Model additionally adjusted for the receipt of LPV/r, IFN-β or remdesivir. Remdesivir for the treatment of COVID-19 -final report Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Effect of colchicine vs. standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: A series of 21 consecutive cases Effect of tocilizumab vs. usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or lifethreatening cytokine release syndrome Centro de Coordinación de Alertas y Emergencias Sanitarias. Documento técnico de manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19) Agencia Española de Medicamentos y Productos Sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study Dexamethasone in hospitalized patients with COVID-19: preliminary report Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Safety and efficacy of anti-IL6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial Can tocilizumab calm the cytokine storm of COVID-19? Efficacy of tocilizumab in patients hospitalized with COVID-19 Use of baricitinib in patients with moderate and severe COVID-19 Online ahead of print Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review Factors associated with COVID-19-related death using OpenSAFELY Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention CS: corticosteroids; HCQ: hydroxychloroquine; IFN-β: interveron-β; IQR: interquartile range; LDH: lactate dehydrogenase; LPV: lopinavir/ritonavir